Species-specific antifungal resistance trends in yeast bloodstream isolates causing candidemia before, during, and after the COVID-19 pandemic: insights from the INVIFAR Mexican multicenter network
Authors:
Open Access
- 4 March 2026
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 45 (6) , 1-14
Abstract
Yeast pathogens represent a major cause of bloodstream infections, with a rising prevalence of non-albicans Candida species displaying variable antifungal resistance patterns that complicate clinical management. This study evaluated antifungal susceptibility in 1,154 bloodstream yeast isolates collected from January 2019 to December 2024 through the INVIFAR (Investigación y Vigilancia de la Farmacorresistencia) multicentric network, encompassing hospital laboratories across diverse patient populations. Isolates were stratified into pre-pandemic, pandemic, and post-pandemic periods to assess temporal changes in resistance patterns. Identification and susceptibility testing were performed using automated systems and standardized CLSI methods. Longitudinal analysis of antifungal susceptibility in Candida albicans, Nakaseomyces glabratus, Candida parapsilosis, Candida tropicalis and Issatchenkia orientalis revealed predominantly stable profiles across pre-, during-, and post-pandemic periods. Statistically significant changes were observed in two instances: a post-pandemic decrease in caspofungin resistance for N. glabratus (adj. p = 0.0377) and a reduction in voriconazole resistance in C. parapsilosis (adj. p = 0.0015). Resistance velocity analysis highlighted a rapid increase in itraconazole resistance for C. parapsilosis, while C. albicans and I. orientalis remained susceptible. These results emphasize that selective pressure and clonal expansion can drive significant resistance shifts, underscoring the need for targeted surveillance and antifungal stewardship.Keywords
This publication has 38 references indexed in Scilit:
- Outbreak of Candida auris infection in a COVID-19 hospital in MexicoClinical Microbiology and Infection, 2021
- General hospital outbreak of invasive candidiasis due to azole-resistant Candida parapsilosis associated with an Erg11 Y132F mutationMedical Mycology, 2020
- A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19Antimicrobial Agents and Chemotherapy, 2020
- The Evolution of Antimicrobial Resistance in Mexico During the Last Decade: Results from the INVIFAR GroupMicrobial Drug Resistance, 2020
- Fluconazole‐resistant Candida parapsilosis strains with a Y132F substitution in the ERG11 gene causing invasive infections in a neonatal unit, South AfricaMycoses, 2020
- Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico: a nationwide surveillance studyJournal of Antimicrobial Chemotherapy, 2013
- Evaluation of Caspofungin Susceptibility Testing by the New Vitek 2 AST-YS06 Yeast Card Using a Unique Collection of FKS Wild-Type and Hot Spot Mutant Isolates, Including the Five Most Common Candida SpeciesAntimicrobial Agents and Chemotherapy, 2013
- Molecular characterization and antifungal susceptibility of theCandida parapsilosisspecies complex of clinical isolates from Monterrey, MexicoMedical Mycology, 2012
- EUCAST Technical note on Amphotericin BClinical Microbiology and Infection, 2011
- Trends in Species Distribution and Susceptibility of Bloodstream Isolates of Candida Collected in Monterrey, Mexico, to Seven Antifungal Agents: Results of a 3-Year (2004 to 2007) Surveillance StudyJournal of Clinical Microbiology, 2008